Given the highly favorable expression pattern of ALK with no/limited detectable protein expression in benign tissues, antibody–drug conjugate or cell-based therapies exploiting the cancer-specific expression of ALK could be attractive options for prostate cancer (49, 50). This evidence concerns the gene ALK and cancer.